Management of inherited von Willebrand disease in 2006.
The aim of treatment of von Willebrand disease (VWD) is to correct the dual defect of hemostasis (i.e., the abnormal platelet adhesion due to reduced and/or dysfunctional von Willebrand factor [VWF] and the abnormal coagulation expressed by low levels of factor [F] VIII). Desmopressin acetate (DDAVP) is the treatment of choice for type 1 VWD because it can induce release of normal VWF from cellular compartments. Prospective studies on biological response versus clinical efficacy of DDAVP in VWD types 1 and 2 are in progress to explore its benefits and limits as a therapeutic option. In type 3 and in severe forms of type 1 and 2 VWD, DDAVP is not effective, and for these patients plasma virally inactivated concentrates containing VWF and FVIII are the mainstay of treatment. Several intermediate- and high-purity VWF/FVIII concentrates are available and have been shown to be effective in clinical practice (bleeding and surgery). New VWF products almost devoid of FVIII are now under evaluation in clinical practice. Although thrombotic events are rare in VWD patients receiving repeated infusions of concentrates, there is some concern that sustained high FVIII levels may increase risk of postoperative venous thromboembolism. Dosage and timing of VWF/FVIII administrations should be planned to keep the FVIII level between 50 and 150 IU/dL. Appropriate dosage and timing in repeated infusions are also very important in patients exposed to secondary long-term prophylaxis for recurrent bleedings.
Federici
Augusto B
AB
Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Medicine and Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli, Regina Elena Foundation, University of Milan, Milan, Italy. augusto.federici@unimi.it
D002986:Clinical Trials as Topic; D003894:Deamino Arginine Vasopressin / Q000378:metabolism / Q000627:therapeutic use; D005169:Factor VIII / Q000378:metabolism; D006405:Hematology / Q000639:trends*; D006801:Humans; D007518:Isoantibodies / Q000737:chemistry; D012306:Risk; D013997:Time Factors; D020246:Venous Thrombosis / Q000188:drug therapy; D014842:von Willebrand Diseases / Q000235:genetics* / Q000628:therapy*; D014841:von Willebrand Factor / Q000378:metabolism
D007518:Isoantibodies; D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin